Monopar Therapeutics Inc. (NASDAQ:MNPR) Sees Large Drop in Short Interest

Monopar Therapeutics Inc. (NASDAQ:MNPR) was the recipient of a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 26,900 shares, a decrease of 62.6% from the October 31st total of 72,000 shares. Based on an average trading volume of 1,230,000 shares, the short-interest ratio is currently 0.0 days. Currently, 0.9% of the shares of the company are sold short.

Insider Activity at Monopar Therapeutics

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan acquired 1,550 shares of the company’s stock in a transaction dated Monday, October 28th. The shares were acquired at an average cost of $16.25 per share, with a total value of $25,187.50. Following the acquisition, the chief financial officer now directly owns 1,550 shares of the company’s stock, valued at approximately $25,187.50. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 34.90% of the stock is owned by insiders.

Monopar Therapeutics Stock Performance

Shares of MNPR traded up $1.25 during trading hours on Wednesday, hitting $20.70. The stock had a trading volume of 90,769 shares, compared to its average volume of 663,874. The firm has a 50-day moving average price of $11.34 and a 200 day moving average price of $6.10. Monopar Therapeutics has a fifty-two week low of $1.40 and a fifty-two week high of $38.50. The firm has a market capitalization of $109.25 million, a price-to-earnings ratio of -10.64 and a beta of 1.09.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09. As a group, analysts predict that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Rodman & Renshaw initiated coverage on shares of Monopar Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $50.00 price target on the stock. HC Wainwright upped their target price on Monopar Therapeutics from $6.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, November 11th.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.